Biologics in polymyositis and dermatomyositis-associated interstitial lung disease

Curr Pharm Biotechnol. 2014;15(6):521-4. doi: 10.2174/138920101506140910145940.

Abstract

Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antigens, CD / immunology
  • Antigens, CD20 / immunology
  • Antigens, Neoplasm / immunology
  • Biological Products / therapeutic use*
  • CD52 Antigen
  • Dermatomyositis / complications
  • Dermatomyositis / drug therapy*
  • Glycoproteins / immunology
  • Humans
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / immunology
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / etiology
  • Polymyositis / complications
  • Polymyositis / drug therapy*
  • Receptors, Interleukin-1 / antagonists & inhibitors
  • Receptors, Interleukin-1 / immunology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, CD20
  • Antigens, Neoplasm
  • Biological Products
  • CD52 Antigen
  • CD52 protein, human
  • Glycoproteins
  • IL6 protein, human
  • Interleukin-6
  • Receptors, Interleukin-1
  • Tumor Necrosis Factor-alpha